Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* has Type 1 or Type 2 diabetes mellitus~* has a history of chronic pain attributable to a symmetrical stocking distribution neuropathy in the lower extremities for a duration of at least six months but less than or equal to five years prior to Screening~Exclusion Criteria:~* has neuropathy secondary to non-diabetic causes~* has a significant neurological disorder or a condition that can cause symptoms that mimic peripheral neuropathy or might confound assessment of PDN~* has other chronic pain with intensity at or greater than the bilateral pain in the feet/toes~* is using an implanted medical device (eg, spinal cord stimulator, intrathecal pump, or peripheral nerve stimulator) for the treatment of pain~* is pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Gel (Type: PLACEBO_COMPARATOR): Placebo Gel is vehicle without clonidine
- Clonidine Topical Gel (ARC-4558) (Type: ACTIVE_COMPARATOR): Clonidine Topical Gel contains 0.1% clonidine hydrochloride

Based on this trial design, predict the completion outcome and termination type (if applicable).